Regression of hepatic adenomata after cessation of selective oestrogen receptor modulator

Liver International

Volumn 29, Issue 1, 2009, Pages 73-

  Carswell, Kirstin A ^a   Belgaumkar, Ajay ^a   Karani, John ^a   Patel, Ameet G ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

AGED; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; FEMALE; GIANT CELL TUMOR; HUMAN; LIVER ADENOMA; LIVER ADENOMATA; LIVER RESECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; TUMOR REGRESSION;

ADENOMA, LIVER CELL; AGED; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 57749181114     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01848.x     Document Type: Article

References (4)

1. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641-7.
2. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001; 65: 125-34.
3. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomised trial of raloxifene. J Natl Cancer Inst 2004; 96: 1751-61.
4. Porter LE, Elm MS, Thiel DHV, Eagon PK. Hepatic estrogen receptor in human liver disease. Gastroenterology 1987; 92: 735-45.